The cost-utility of open prostatectomy compared with active surveillance in early localised prostate cancer

BMC Health Services Research

Volumn 14, Issue 1, 2014, Pages

  Koerber, Florian ^a   Waidelich, Raphaela ^b   Stollenwerk, Björn ^a   Rogowski, Wolf ^a,c  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Active surveillance; Cost effectiveness; Cost utility analysis; Decision analysis; Early evaluation; Economic evaluation; Prostate cancer

Indexed keywords

CONFIDENCE INTERVAL; COST; DECISION SUPPORT SYSTEM; ECONOMICS; HUMAN; MALE; PATHOPHYSIOLOGY; PROBABILITY; PROCEDURES; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY ADJUSTED LIFE YEAR; WATCHFUL WAITING;

CONFIDENCE INTERVALS; COSTS AND COST ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; MALE; MARKOV CHAINS; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; WATCHFUL WAITING;

EID: 84901000890     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-14-163     Document Type: Article

References (66)

1. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 2 69 90 10.3322/caac.20107 21296855
2. Statistisches Bundesamt, Statistisches Jahrbuch 2011 für die Bundesrepublik Deutschland [Statistical Yearbook 2011 for the Federal Republic of Germany] Wiesbaden: Federal Statistical Office 2011
3. Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. Moul JW, Wu H, Sun L, McLeod DG, Amling C, Lance R, Kusuda L, Donahue T, Foley J, Chung A, Sexton W, Soderdahl D, Rich NM, Surgery 2002 132 2 213 219 10.1067/msy.2002.125315 12219014 (Pubitemid 35024764)
4. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, Campbell-Walsh Urology Philadelphia: Elsevier Health Sciences 10 2011
5. Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. http://www.awmf.org/uploads/tx-szleitlinien/043-022OLl-S3- Prostatakarzinom-2011.pdf
6. Benefit assessment by the Federal Joint Committee: assessment of treatment strategies for low risk prostate cancer. Schmedders M, Janatzek S, Zimmer B, Urologe A 2011 50 8 938 943 10.1007/s00120-011-2545-3 21720836
7. Radical prostatectomy versus watchful waiting in early prostate cancer. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Haggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Steineck G, Adami HO, Johansson JE, SPCG-4 Investigators, N Engl J Med 2011 364 18 1708 1717 10.1056/NEJMoa1011967 21542742
8. Prostate cancer epidemiology. Gronberg H, Lancet 2003 361 9360 859 864 10.1016/S0140-6736(03)12713-4 12642065 (Pubitemid 36331852)
9. Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Popiolek M, Rider JR, Andrén O, Andersson S-O, Holmberg L, Adami H-O, Johansson J-E, Eur Urol 2013 63 3 428 435 10.1016/j.eururo.2012.10.002 23084329
10. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Klotz L, Urol Oncol 2006 24 1 46 50 10.1016/j.urolonc. 2005.07.002 16414494 (Pubitemid 43097357)
11. EAU guidelines on prostate cancer: part 1: screening, diagnosis, and treatment of clinically localised disease. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, European Association of Urology, Eur Urol 2011 59 1 61 71 10.1016/j.eururo.2010.10.039 21056534
12. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Boorjian SA, Eastham JA, Graefen M, Guillonneau B, Karnes RJ, Moul JW, Schaeffer EM, Stief C, Zorn KC, Eur Urol 2012 61 4 664 675 10.1016/j.eururo.2011.11.053 22169079
13. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian prostate cancer group-4 randomised trial. Johansson E, Steineck G, Holmberg L, Johansson JE, Nyberg T, Ruutu M, Bill-Axelson A, Lancet Oncol 2011 12 9 891 899 10.1016/S1470-2045(11)70162-0 21821474
14. Active surveillance for prostate cancer: a systematic review of the literature. Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS, Eur Urol 2012 62 6 976 983 10.1016/j.eururo.2012.05.072 22698574
15. Active surveillance: towards a new paradigm in the management of early prostate cancer. Parker C, Lancet Oncol 2004 5 2 101 106 10.1016/S1470-2045(04) 01384-1 14761814 (Pubitemid 38145893)
16. Active surveillance in men with localized prostate cancera systematic review. Dahabreh IJ, Chung M, Balk EM, Yu WW, Mathew P, Lau J, Ip S, Ann Intern Med 2012 156 8 582 590 10.7326/0003-4819-156-8-201204170-00009 22351515
17. Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, Lin DW, Carroll PR, Carter HB, Etzioni R, Clin Cancer Res 2012 18 19 5471 5478 10.1158/1078-0432.CCR-12-1502 23008476
18. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E, Value Health 2013 16 2 231 250 10.1016/j.jval.2013.02. 002 23538175
19. Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System. https://www.iqwig.de/en/methods/methods-papers/ health-economic-evaluation.3022.html
20. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Hummel S, Simpson EL, Hemingway P, Stevenson MD, Rees A, Health Technol Assess 2010 14 47 1 108 iii-iv
21. Clinical and demographic characteristics associated with prostate cancer progression in patients on active surveillance. Iremashvili V, Soloway MS, Rosenberg DL, Manoharan M, J Urol 2012 187 5 1594 1599 22425088
22. Active surveillance for early-stage prostate cancer: review of the current literature. Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE Jr, Wallace ME, Kantoff PW, Carroll PR, Cancer 2008 112 8 1650 1659 10.1002/cncr.23373 18306379 (Pubitemid 351536825)
23. Short- and long-term complications of open radical prostatectomy according to the Clavien classification system. Constantinides CA, Tyritzis SI, Skolarikos A, Liatsikos E, Zervas A, Deliveliotis C, BJU Int 2009 103 3 336 340 10.1111/j.1464-410X.2008.08080.x 18782300
24. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Veldeman L, Madani I, Hulstaert F, De Meerleer G, Mareel M, De Neve W, Lancet Oncol 2008 9 4 367 375 10.1016/S1470-2045(08)70098-6 18374290 (Pubitemid 351411653)
25. Wood S, Generalized Additive Models: An Introduction with R Boca Raton: Taylor & Francis 2006
26. Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Ara R, Brazier JE, Value Health 2011 14 4 539 545 10.1016/j.jval.2010.10.029 21669378
27. Health status of adults in germany: results from a representative survey using the EuroQol 5D (EQ-5D). Mielck A, Vogelmann M, Schweikert B, Leidl R, Gesundheitswesen 2010 72 8-9 476 486 19802780
28. A review and meta-analysis of prostate cancer utilities. Bremner KE, Chong CA, Tomlinson G, Alibhai SM, Krahn MD, Med Decis Making 2007 27 3 288 298 10.1177/0272989X07300604 17502448 (Pubitemid 46801746)
29. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Stewart ST, Bhatnagar V, Sweeney CJ, Stahl JE, McMahon PM, JAMA 2010 304 21 2373 2380 10.1001/jama.2010.1720 21119084
30. A reference set of health utilities for long-term survivors of prostate cancer: population-based data from Ontario, Canada. Krahn MD, Bremner KE, Alibhai SM, Ni A, Tomlinson G, Laporte A, Naglie G, Qual Life Res 2013 22 10 2951 2962 10.1007/s11136-013-0401-1 23564620
31. Utilities for prostate cancer health states in men aged 60 and older. Stewart ST, Lenert L, Bhatnagar V, Kaplan RM, Med Care 2005 43 4 347 355 10.1097/01.mlr.0000156862.33341.45 15778638 (Pubitemid 40515624)
32. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer. Sommers BD, Beard CJ, D'Amico AV, Dahl D, Kaplan I, Richie JP, Zeckhauser RJ, Cancer 2007 110 10 2210 2217 10.1002/cncr.23028 17893907 (Pubitemid 350100742)
33. Active surveillance versus surgery for low risk prostate cancer: a clinical decision analysis. Liu D, Lehmann HP, Frick KD, Carter HB, J Urol 2012 187 4 1241 1246 22335873
34. Kassenärztliche Bundesvereinigung. http://www.kbv.de/
35. Intitut für Entgeltsysteme im Krankenhaus. http://www.g-drg.de/cms/
36. Research Institute of the AOK. http://wido.de/arzneimittel.html
37. Complications following prostate needle biopsy requiring hospital admission or emergency department visits-experience from 1000 consecutive cases. Pinkhasov GI, Lin YK, Palmerola R, Smith P, Mahon F, Kaag MG, Dagen JE, Harpster LE, Reese CT, Raman JD, BJU Int 2012 110 3 369 374 10.1111/j.1464-410X. 2011.10926.x 22313996
38. The cost to the United Kingdom National Health Service of managing erectile dysfunction: the impact of sildenafil and prescribing restrictions. Wilson EC, McKeen ES, Scuffham PA, Brown MC, Wylie K, Hackett G, Pharmacoecon 2002 20 13 879 889 10.2165/00019053-200220130-00002 (Pubitemid 35252839)
39. Costs of prostate cancer, metastatic to the bone, in the Netherlands. Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA, Eur Urol 2003 43 3 226 232 10.1016/S0302-2838(03)00007-1 12600424 (Pubitemid 36314233)
40. Radical prostatectomy versus observation for localized prostate cancer. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T, Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group, N Engl J Med 2012 367 3 203 213 10.1056/NEJMoa1113162 22808955
41. Results from a prostate cancer admixture mapping study in African-American men. Bock CH, Schwartz AG, Ruterbusch JJ, Levin AM, Neslund-Dudas C, Land SJ, Wenzlaff AS, Reich D, McKeigue P, Chen W, Heath EI, Powell IJ, Kittles RA, Rybicki BA, Hum Genet 2009 126 5 637 642 10.1007/s00439-009-0712-z 19568772
42. Germ-line mutations of the macrophage scavenger receptor 1 gene: association with prostate cancer risk in African-American men. Miller DC, Zheng SL, Dunn RL, Sarma AV, Montie JE, Lange EM, Meyers DA, Xu J, Cooney KA, Cancer Res 2003 63 13 3486 3489 12839931 (Pubitemid 36793026)
43. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, Andersson SO, Spangberg A, Busch C, Nordling S, Palmgren J, Adami HO, Johansson JE, Norlén BJ, Scandinavian Prostatic Cancer Group Study Number 4, N Engl J Med 2002 347 11 781 789 10.1056/NEJMoa012794 12226148 (Pubitemid 34988336)
44. Do older men benefit from curative therapy of localized prostate cancer? Alibhai SM, Naglie G, Nam R, Trachtenberg J, Krahn MD, J Clin Oncol 2003 21 17 3318 3327 10.1200/JCO.2003.09.034 12947068 (Pubitemid 46606266)
45. Active Surveillance and Radical Prostatectomy Final Appraisal. http://www.icer-review.org/publications-and-resources/reports/
46. Briggs A, Claxton K, Sculpher M, Decision modelling for health economic evaluation Oxford: Oxford Univ. Press 1 2006
47. Prevalence of lower urinary tract symptoms in men aged 45-79 years: a population-based study of 40 000 Swedish men. Andersson SO, Rashidkhani B, Karlberg L, Wolk A, Johansson JE, BJU Int 2004 94 3 327 331 10.1111/j.1464-410X. 2004.04930.x 15291861 (Pubitemid 39120173)
48. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Hanks GE, Zietman AL, The J of Urol 2005 173 3 797 802 (Pubitemid 40239344)
49. Decision-analytical modelling of costs per QALY in the context of the German Social Law. Rogowski WH, Landauer M, John J, Gesundheitswesen 2009 71 11 739 750 10.1055/s-0029-1220756 19551622
50. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Grosse SD, Expert Rev Pharmacoecon Outcomes Res 2008 8 2 165 178 10.1586/14737167.8.2.165 20528406 (Pubitemid 351959547)
51. German recommendations on health economic evaluation: third and updated version of the Hanover consensus. Graf von der Schulenburg JM, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, Mittendorf T, Rebscher H, Schoeffski O, Vauth C, Volmer T, Wahler S, Wasem J, Weber C, Hanover Consensus Group, Value Health 2008 11 4 539 544 10.1111/j.1524-4733.2007.00301.x 18194408 (Pubitemid 352032814)
52. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Lee PA, McMahon PM, Ann Intern Med 2013 158 12 853 860 10.7326/0003-4819-158-12-201306180-00002 23778902
53. Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. Keegan KA, Dall'Era MA, Durbin-Johnson B, Evans CP, Cancer 2012 118 14 3512 3518 10.1002/cncr.26688 22180322
54. The contemporary concept of significant versus insignificant prostate cancer. Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm M-O, Bjartell AS, Montorsi F, Freedland SJ, Erbersdobler A, van der Kwast TH, Eur Urol 2011 60 2 291 303 10.1016/j.eururo.2011.05.006 21601982
55. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). Epstein JI, Walsh PC, Brendler CB, J Urol 1994 152 5 Pt 2 1721 1729 7523719 (Pubitemid 24322614)
56. Undergrading and understaging in patients with clinically insignificant prostate cancer who underwent radical prostatectomy. Oliveira IS, Pontes-Junior J, Abe DK, Crippa A, Dall'oglio MF, Nesralah AJ, Leite KR, Reis ST, Srougi M, Int Braz J Urol 2010 36 3 292 299 20602821
57. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Sutcliffe P, Hummel S, Simpson E, Young T, Rees A, Wilkinson A, Hamdy F, Clarke N, Staffurth J, Health Technol Assess 2009 13 5 1 219 iii, xi-xiii
58. The effect of minimally invasive and open radical prostatectomy surgeon volume. Choi WW, Gu X, Lipsitz SR, D'Amico AV, Williams SB, Hu JC, Urol Oncol 2012 30 5 569 576 10.1016/j.urolonc.2010.06.009 20822929
59. The surgical learning curve for prostate cancer control after radical prostatectomy. Vickers AJ, Bianco FJ, Serio AM, Eastham JA, Schrag D, Klein EA, Reuther AM, Kattan MW, Pontes JE, Scardino PT, J Natl Cancer Inst 2007 99 15 1171 1177 10.1093/jnci/djm060 17652279 (Pubitemid 47233067)
60. Dollars may not buy as many QALYs as we think: a problem with defining quality-of-life adjustments. Fryback DG, Lawrence WF Jr, Med Decis Making 1997 17 3 276 284 10.1177/0272989X9701700303 9219187 (Pubitemid 27282028)
61. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Welte R, Feenstra T, Jager H, Leidl R, Pharmacoecon 2004 22 13 857 876 10.2165/00019053-200422130-00004 (Pubitemid 39273956)
62. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL, Ann Intern Med 2008 148 6 435 448 10.7326/0003-4819-148- 6-200803180-00209 18252677 (Pubitemid 351665443)
63. - 272 The HAROW study-an observational health service study, capturing current low-risk-prostate cancer treatment practice patterns in Germany. Becker A, Kluth LA, Beermann S, Seiler D, Recker F, Chun FK, Weissbach L, Eur Urol Suppl 2013 12 1 272 10.1016/S1569-9056(13)60759-9
64. PREFERE-the German prostatic cancer study: questions and claims surrounding study initiation in January 2013. Wiegel T, Albers P, Bussar-Maatz R, Gottberg A, Harter M, Kieser M, Kristiansen G, Nettekoven G, Martus P, Schmidberger H, Wellek S, Stöckle M, Urologe A 2013 52 4 576 579 23571802
65. Early evaluation and value-based pricing of regenerative medicine technologies. Koerber F, Rolauffs B, Rogowski W, Regen Med 2013 8 6 747 758 10.2217/rme.13.69 24147530
66. Information for decision making by patients with early-stage prostate cancer: a comparison across 9 countries. Feldman-Stewart D, Capirci C, Brennenstuhl S, Tong C, Abacioglu U, Gawkowska-Suwinska M, van Gils F, Heyda A, Igdem S, Macias V, Grillo IM, Moynihan C, Pijls-Johannesma M, Parker C, Pimentel N, Wördehoff H, Med Decis Making 2011 31 5 754 766 10.1177/ 0272989X10395029 21273630